

Descripción de pacientes con cáncer activo y tromboembolismo pulmonar agudo diagnosticado por angiotomografía de tórax con contraste (ANGIOTAC) durante el 2013 al 2019. Hospital Militar Central, Bogotá-Colombia

Description of patients with active cancer and acute pulmonary thromboembolism diagnosed by contrast-contrasted chest angiotomography (CT-ANGIO) during 2013 to 2019. Hospital Militar Central, Bogotá-Colombia

Oa JAR, Ranados MAG OA. Curso clínico y supervivencia en embolia pulmonar. 2008;111

1. White RH. The Epidemiology of Venous Thromboembolism. 2003;4–8.
2. Press D. Deep vein thrombosis : a clinical review. 2011;59–69.
3. Giordano NJ, Jansson PS, Young MN, Hagan KA, Kabrhel C. Epidemiology, Pathophysiology, Stratification, and Natural History of Pulmonary Embolism. *Tech Vasc Interv Radiol* [Internet]. 2017;20(3):135–40. Available from: <http://dx.doi.org/10.1053/j.tvir.2017.07.002>
4. Connolly GC, Francis CW. Cancer-associated thrombosis. :684–91.
5. Gussoni G, Frasson S, La Regina M, Di Micco P MM. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. *Thromb Res*. 2013;131:24–30.
6. Khorana AA, Connolly GC. Assessing Risk of Venous Thromboembolism in the Patient With Cancer. 2009;27(29).
7. Svensson PJ, Sja A. Venous thromboembolism and cancer risk. 2017;68–73.
8. Horsted, F.; West, J.; Grainge MJ. Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. *Plos Med*. 2012;9.

9. Hisada Y MN. Cancer-associated pathways and biomarkers of venous thrombosis. *Blood*. 2017;
10. Cronin-Fenton, D.P.; Søndergaard, F.; Pedersen, L.A.; Fryzek, J.P.; Cetin, K.; Acquavella, J.; Baron JA., Sørensen H. Hospitalisation for venous thromboembolism in cancer patients and the general population: A population-based cohort study in Denmark, 1997–2006. *Br J Cancer*. 2010;103(947).
11. Blom JW, Osanto S RF. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. *J Thromb Haemost*. 2004;1760.
12. Chew, H.K.; Wun, T.; Harvey, D.; Zhou, H.; White R. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. *Arch Intern Med*. 2006;166:458–64.
13. Haddad, T.C.; Greeno E. Chemotherapy-induced thrombosis. *Thrombo Res*. 2006;118:555–68.
14. Fuentes, H.E.; Tafur, A.J.; Caprini J. Cancer-associated thrombosis. *Disease-a-Month*. 2016;62:121–58.
15. Alcalay, A.; Wun, T.; Khatri, V.; Chew, H.K.; Harvey, D.; Zhou, H.; White R. Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival. *J Clin Oncol*. 2006;24(1112–1118).
16. Yap KPL MD. Deep Vein Thrombosis and Malignancy: A Surgical Oncologist’s Perspective. *Asian J Surg*. 2004;249–54.
17. Kiyokawa H, Ph D, Katoh H, Ph D. Tumor-Related Leukocytosis Is Linked with Poor Prognosis in Patients with Lung Carcinoma M : F. 2001;2399–405.
18. Hisada Y MN. Cancer-associated pathways and biomarkers of venous thrombosis. *Blood*.

2017;130:1499–506.

19. Geddings JE MN. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. *Blood*. 2013;122(11):1873–80.
20. Factors R, Metharom P. Cancer-Associated Thrombosis : An Overview of. 2018;1–21.
21. Li A, Garcia DA, Lyman GH, Carrier M, Hutchinson F. Direct Oral Anticoagulant (DOAC) versus Low-Molecular-Weight Heparin (LMWH) for Treatment of Cancer Associated Thrombosis (CAT): A Systematic Review and Meta-Analysis. 2020;158–63.
22. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM CG. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. *Arch Intern Med*. 2000;181–8.
23. Morales M Milena, Arboleda R Luis BEA. Anticoagulación en enfermedad tromboembólica venosa. *Rev Chil Cardiol*. 2019;38(2):122–31.
24. Nakamura M, Yamada N. Current management of venous thromboembolism in Japan : Current epidemiology and advances in anticoagulant therapy. *J Cardiol [Internet]*. 2015;66(6):451–9. Available from: <http://dx.doi.org/10.1016/j.jjcc.2015.03.012>
25. Article O. Incidence of venous thromboembolism in different ethnic groups : a regional direct comparison study. 2014;(November 2013):214–9.
26. Of T, Art THE. Chronic complications of venous thromboembolism. 2017;1531–40.
27. Heit JA. Epidemiology of venous thromboembolism. 2015;12(8):464–74.
28. Nancy L. Shapiro, PharmD, FCCP, BCPS, Snehal H. Bhatt, PharmD, BCPS3. Critical review and update on the treat-ment of acute and chronic pulmonary embolism. *J Pharm Pract*. 2015;29(1).

29. Phillippe HM. Overview of venous thromboembolism. *Am J Manag Care*. 2017;23(20):S376–82.
30. Kakkar A, Konstantinides S V, Mccumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis A Major Contributor to Global Disease Burden. 2014;2363–71.
31. Ghazi S. Alotaibi, Cynthia Wu, Ambikaipakan Senthilselvan MSM. Secular Trends in Incidence and Mortality of Acute Venous Thromboembolism: The AB-VTE Population-Based Study. *Am J Med*. 2016;129(8).
32. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep Vein Thrombosis and Pulmonary Embolism in Two Cohorts : The Longitudinal Investigation of Thromboembolism Etiology. 2004;19–25.
33. Becattini C, Agnelli G. Treatment of Venous Thromboembolism With New Anticoagulant Agents. 2016;67(16).
34. Karipott A, Shaaban HS, Maroules M, Guron G. The clinical characteristics of pulmonary embolism in patients with malignancy: A single medical institutional experience. *N Am J Med Sci*. 2012;4(11):600–4.
35. Singh G, Rathi AK, Singh K SD. Venous thromboembolism in cancer patients - magnitude of problem, approach, and management. *Indian J Cancer*. 2017;54(1):308–12.
36. Paul D. Stein, Afzal Beemath, Frederick A. Meyers, Elias Skaf, Julia Sanchez REO. Incidence of Venous Thromboembolism in Patients Hospitalized with Cancer. *Am J Med*. 2006;119(1):60–8.
37. Barbui T DS V. Management of venous thromboembolism in myeloproliferative neoplasms. *Curr Opin Hematol*. 2017;24(2):108–14.
38. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent

venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood*. 2002;100(10):3484–8.

39. Dennis R, Arboleda MN De, Rodríguez MN, Salazar MS, Posada PS GD. Estudio nacional sobre tromboembolismo venoso en población hospitalaria en Colombia. *Acta Medica Colomb*. 1996;21:55–63.
40. Suárez OGP. Caracterización clínica de pacientes con enfermedad tromboembólica asociada a cáncer en el Instituto Nacional de Cancerología. *Univ Nac Colomb*. 2018;
41. Oa JAR, Ranados MAG OA. Curso clínico y supervivencia en embolia pulmonar. 2008;111.

42.

- A. Naess, S. C. Christiansen, P. Romundstad . Incidence and mortality of venous thrombosis: a population – based study. *Journal of Thrombosis and Haemostasis*, 5: 692–699